Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer H0150

Resumen| PDF

Revisión

Patofisiología y principios terapéuticos de las náuseas y vómitos inducidos por quimioterapia

Publicado: 2023-03-29

VOLUMEN 36, NÚM. 2, marzo-abril (2022), PAG. 59-112

Logo Descargas Número de descargas: 11486 Logo Visitas Número de visitas: 680 Citas Citas: 0

Compártelo:

Las náuseas y vómitos inducidos por quimioterapia (NVIQ) representan una complicación frecuente en el paciente oncológico. Actualmente su fisiopatología no está esclarecida por completo. Parecer ser que la emesis puede estar relacionada con distintos neurotransmisores que se liberan predominantemente en el tracto gastrointestinal ejerciendo su acción en áreas del tronco encefálico encargadas del reflejo emético. Hay tres tipos de NVIQ: agudos, tardíos y anticipatorios; saber reconocerlos es fundamental para su correcto manejo y prevención. La probabilidad de aparición de NVIQ está determinada por factores que van a depender del paciente (edad, sexo, alcohol…) y factores que están más relacionados con el tratamiento antineoplásico (tipo de fármaco, velocidad y formas de administración). En la actualidad disponemos de una gran variedad de fármacos antieméticos entre los que destacan los antagonistas del receptor de la serotonina y de la neurocinina-1 (NK1).

Palabras Clave: Náuseas. Vómitos. Quimioterapia. Neurotransmisor.

Descargar PDF

Bibliografía
Artículos Relacionados

Clark-Snow R, Affronti ML, Rittenberg CN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018;26(2):557-64.

Ferretiz López G, Cuéllar Guzmán LF, Cárdenas Herrera N. Clasificación y tratamiento de náusea y vómito postoperatorio en el paciente oncológico sometido a cirugía. Revista Chilena de Anestesia 2020;49(2):223-36.

Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358(23):2482-94.

Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 2013;14(6):757-66.

Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994;15(4):301-20.

Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990;68(2):230-6.

Miller AD, Wilson VJ. ‘Vomiting center’ reanalyzed: an electrical stimulation study. Brain Res 1983;270(1):154-8.

Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992;43(3):295-315.

Bountra C, Gale JD, Gardner CJ, Jordan CC, Kilpatrick GJ, Twissell DJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 1996;53(Suppl 1):102-9.

Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5(2):193-230.

Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985;7(2):191-211.

Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83(9):613-20.

Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999;375(1-3):51-60.

Henson LA, Maddocks M, Evans C, Davidson M, Hicks S, Higginson IJ. Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. J Clin Oncol 2020;38(9):905-14.

Miao J, Liu X, Wu C, Kong H, Xie W, Liu K. Effects of acupressure on chemotherapy-induced nausea and vomiting - a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials. Int J Nurs Stud 2017;70:27-37.

Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin- induced emesis. Definition and validation of a predictive logistic model. Cancer 1989;64(5):1117-22.

Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 1994;2(3):161-6.

Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 1998;12(3 Suppl 4):32-7.

Suji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer 2019(3):1139-47.

Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, et al. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res 2018;10:4249-55.

Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20(12):2805-11.

Remblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21(11):2147-55.

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - state of the art. Support Care Cancer 2011;19(Suppl 1):S43-7.

Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986;70(5):555-63.

Jordan NS, Schauer PK, Schauer A, Nightingale C, Golub G, Martin RS, et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985;3(4):559-61.

Vaid AK, Gupta S, Doval DC, Agarwal S, Nag S, Patil P, et al. Expert Consensus on Effective Management of Chemotherapy- Induced Nausea and Vomiting: An Indian perspective. Front Oncol 2020;10:400.

Viale PH. Chemotherapy-induced nausea and vomiting: updates and recommendations. J Adv Pract Oncol 2018;9(2):150-2.

Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37(9):1276-86.

Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010;5(1):105-11.

Turner S, Mathews L, Pandharipande P, Thompson R. Dolasetron- induced torsades de pointes. J Clin Anesth 2007;19(8):622-5.

Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? - a systematic review and meta-analysis. Support Care Cancer 2018;26(1):21-32.

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29(31):4189-98.

Szmyd B, Rogut M, Białasiewicz P, Gabryelska A. The impact of glucocorticoids and statins on sleep quality. Sleep Med Rev 2021;55:101380.

Masiongale AJ, Garvin JT, Murphy MJ, Hooper VD, Odom-Forren J, Masiongale JI, et al. Reexamining metoclopramide’s role in the prevention of postoperative nausea and vomiting: a secondary analysis. AANA J 2018;86(3):213-9.

Storz E, Gschwend JE, Retz M. Chemotherapy-induced nausea and vomiting: current recommendations for prophylaxis. Urologe A 2018;57(5):532-42.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35(28):3240.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27:v119-v133.

Umar RM. Drug-drug interactions between antiemetics used in cancer patients. J Oncol Sci 2018;4(3):142-6.

Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995;18(2):170-5.

Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double- blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993;11(7):1384-90.

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF